George Eby Research Institute, 14909-C Fitzhugh Road, Austin, Texas 78736, USA.
Med Hypotheses. 2010 Apr;74(4):649-60. doi: 10.1016/j.mehy.2009.10.051. Epub 2009 Nov 27.
Sixty percent of cases of clinical depression are considered to be treatment-resistant depression (TRD). Magnesium-deficiency causes N-methyl-d-aspartate (NMDA) coupled calcium channels to be biased towards opening, causing neuronal injury and neurological dysfunction, which may appear to humans as major depression. Oral administration of magnesium to animals led to anti-depressant-like effects that were comparable to those of strong anti-depressant drugs. Cerebral spinal fluid (CSF) magnesium has been found low in treatment-resistant suicidal depression and in patients that have attempted suicide. Brain magnesium has been found low in TRD using phosphorous nuclear magnetic resonance spectroscopy, an accurate means for measuring brain magnesium. Blood and CSF magnesium do not appear well correlated with major depression. Although the first report of magnesium treatment for agitated depression was published in 1921 showing success in 220 out of 250 cases, and there are modern case reports showing rapid terminating of TRD, only a few modern clinical trials were found. A 2008 randomized clinical trial showed that magnesium was as effective as the tricyclic anti-depressant imipramine in treating depression in diabetics and without any of the side effects of imipramine. Intravenous and oral magnesium in specific protocols have been reported to rapidly terminate TRD safely and without side effects. Magnesium has been largely removed from processed foods, potentially harming the brain. Calcium, glutamate and aspartate are common food additives that may worsen affective disorders. We hypothesize that - when taken together - there is more than sufficient evidence to implicate inadequate dietary magnesium as the main cause of TRD, and that physicians should prescribe magnesium for TRD. Since inadequate brain magnesium appears to reduce serotonin levels, and since anti-depressants have been shown to have the action of raising brain magnesium, we further hypothesize that magnesium treatment will be found beneficial for nearly all depressives, not only TRD.
百分之六十的临床抑郁症病例被认为是治疗抵抗性抑郁症(TRD)。镁缺乏会导致 N-甲基-D-天冬氨酸(NMDA)偶联钙通道偏向开放,从而导致神经元损伤和神经功能障碍,这在人类中可能表现为重度抑郁症。给动物口服镁会产生类似强效抗抑郁药物的抗抑郁作用。在治疗抵抗性自杀性抑郁症和自杀未遂患者中,发现脑脊髓液(CSF)中的镁含量较低。使用磷核磁共振光谱法发现,TRD 患者的大脑镁含量较低,这是一种准确测量大脑镁的方法。血液和 CSF 中的镁含量似乎与重度抑郁症没有很好的相关性。尽管镁治疗激越性抑郁症的第一份报告发表于 1921 年,显示 250 例中有 220 例成功,但现代病例报告显示 TRD 迅速终止,仅发现少数现代临床试验。2008 年的一项随机临床试验表明,镁与三环抗抑郁药丙咪嗪在治疗糖尿病患者的抑郁症方面同样有效,且没有丙咪嗪的任何副作用。据报道,在特定方案中静脉内和口服镁可安全且无副作用地迅速终止 TRD。镁已从加工食品中大量去除,可能对大脑有害。钙、谷氨酸和天冬氨酸是常见的食品添加剂,可能会加重情感障碍。我们假设,- 当一起考虑时 - 有足够的证据表明,饮食中镁不足是 TRD 的主要原因,医生应该为 TRD 开镁。由于大脑中镁不足似乎会降低 5-羟色胺水平,并且抗抑郁药已被证明具有提高大脑镁的作用,我们进一步假设镁治疗将对几乎所有抑郁症患者,而不仅仅是 TRD 患者有益。